5th August 2026

To

The Secretary	The Secretary
BSE Limited	The National Stock Exchange of India Limited
Phiroze Jeejeebhoy Towers	Exchange Plaza, C-1, Block G,
Dalal Street	Bandra-Kurla Complex, Bandra (E)
Mumbai 400 001	Mumbai 400 051
Scrip Code: 500674	Symbol: SANOFI

Sub: Investor / Analysts Call - Presentation

Dear Sir / Madam,

We refer to our intimation dated 23rd July 2026, informing about the scheduling of Investor / Analysts Call for update on Unaudited Financial Results for the quarter and half year ended 30th June 2026.

In this regard, pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed presentation that will be made during the Call for your reference and for dissemination to the investors.

The presentation is also being uploaded on the Company's website Analyst / Investor Meet.

Kindly take the above information on record.

Yours faithfully

For **Sanofi India Limited**

Haresh
Bachubhai Vala

Digitally signed by Haresh Bachubhai Vala
Date: 2026.08.05 13:06:40 +05'30'

Haresh Vala
Company Secretary & Compliance Officer
Membership No: A18246

Encl: a/a

Sanofi India Limited, Sanofi House, CTS No. 117-B, L&T Business Park, Saki Vihar Road, Powai, Mumbai 400 072 - India - Tel.: +91(22) 2803 2000 - Fax: +91(22) 2803 2939
Corporate Identity Number: L24239MH1956PLC009794 Website: www.sanofiindialtd.com | www.sanofi.in Email: igrc.sil@sanofi.com

sanofi

Sanofi India Limited

Investors call Q2/26

5th August 2026



Disclaimer

This Release / Communication, except for the historical information, may contain statements, including the words or phrases such as expects, anticipates, intends, will, would, undertakes, aims, estimates, contemplates, seeks to, objective, goal, projects, should and similar expressions or variations of these expressions or negatives of these terms indicating future performance or results, financial or otherwise, which are forward looking statements. These forward looking statements are based on certain expectations, assumptions, anticipated developments and other factors which are not limited to, risk and uncertainties regarding fluctuations in earnings, market growth, competition and the pricing environment in the market, customer relationship and supply chain sources and those factors which may affect our ability to implement business strategies successfully, namely changes in regulatory environments, geo-political stability, costs etc. The Company, therefore, cannot guarantee that the forward-looking statements made herein shall be realized. The Company, based on changes as stated above, may alter, amend, modify or make necessary corrective changes in any manner to any such forward looking statement contained herein or make written.

Presenters

Deepak Arora
General Manager Pharma India and Country Lead

Rachid Ayari
CFO India and Finance BP General Medicines

sanofi

Q2.26 Domestic results:
Strong momentum further boosted by diabetes business



- Diabetes business continues to grow above market growth. Double Digit growth powered by innovative portfolio.
- Acceleration in public sector by 70% with opening of new accounts for Toujeo & Soliqua
- Continued RoI from partnerships with expanded footprint
- Continuous optimization of resources & Profit before tax

sanofi

Where Scale Meets Innovation: *Our Diabetes Value Proposition*

Own & Grow

Own the Basal Market Leadership

LANTUS insulin glargine

- Market leader: 47% MS by value
- Volume acceleration:+6%

Toujeo

- Preferred 2nd gen basal insulin (11% MS by value)

SOLIQUA insulin glargine & lixisenatide injection

- Market shaping to accelerate reach

Basal analog: Market Share

- 58% by value
- 61% by volume

Innovate

Expanding RWE narrative & Indian datasets to strengthen Toujeo & Soliqua positioning.

- **LANDMARC RWE Study**: Scientific evidence dissemination and KOL advocacy to address unmet need in India
- **Soliqua & Toujeo RWE publications**
- **Preparing for Novel devices & AI platforms to strengthen PSP**

Extend

Tapping the potential of Public Sector

- Entry in CARE Accounts with a growth of 70% with Innovative Portfolio in Diabetes
- Digital Outreach (Tier II/III)

Source for market share:
IQVIA MAT June 2026

Leverage existing diabetes portfolio for sustainable & profitable growth

CSR - 2026 Update: *Reaching out to build stronger communities*

H1 '26 Impact



600,000+

direct beneficiaries to be reached in 2026

Kids and Diabetes in Schools (KiDS)

- **400+** schools
- **450+** teachers
- **80,000+** students*

*Academic year begins in June

MoU signed with NHM, MP

- KiDS (Piloted in Bhopal)
- MMUs (Planned for H2)
- Strengthening rare disease ecosystem

Mobile Medical Units (MMUs)

- **156,000+** screened
- **71,000+** diagnosed*
- **64,000+** treated

* 5,000+ counselled for lifestyle modification & also referred to the PHC for further treatment

₹ in Mio

Total income Q2/2026



Total income YTD June/2026



sanofi

- Other op income: Mainly services
- Other income: Mainly Interest on deposit & FX gain

Net sales Q2/2026:+8%
Strong quarter for domestic sales



H1/2026:Almost flat
Domestic Impacted by one off from 2025



Other: is mainly related to Consumer health business in 2024

₹ in Mio

Operating expenses*| *2025-2026*

Increase focus on financial discipline & optimization





sanofi

*:Depreciation & finance cost not included as there is no Major fluctuation

Profit before tax & excep items | *2025-2026*

₹ in Mio

Double digit Profitable growth





sanofi

Continued *progress* and clear *priorities*

	People	*Execution*	*Business*	*Financials*
Decisions	• **Building right capabilities with Leadership changes and focus**	**Transformed business model** Strategic transformation complete - focus on Insulin & winning partnership model for legacy brands	• **Future Ready Go-To-Market Capabilities**	• **2026 marks a year of acceleration for diabetes business unit with 17% Gr in 1H'26** : modernized our business model supporting sustainable, profitable growth
Priorities and focus	• AI Samvaad: AI readiness	• **Delivering results today**: Strong execution driving growth and significant margin expansion through operational excellence • **Positioned for tomorrow**: Future-ready capabilities position SIL to capture India's high-growth diabetes opportunity	• Customer Centric Approach • AI enabled initiatives • Innovative Customer Journey Orchestrations	• Diabetes BU 17% Growth • Partnership stabilizing while headwinds in export business • Strong Q2 with19% Profit Before Tax driven by the business & OPEX efficiency through

sanofi